United Therapeutics and Sagimet Biosciences Shares Drop After Goldman Sachs Issues 'Sell' Ratings
Shares of United Therapeutics (UTHR) and Sagimet Biosciences (SGMT) declined on Thursday following a downgrade from Goldman Sachs, which issued Sell ratings for both stocks. The move came as the firm resumed coverage of several biotech companies after an extended period without active recommendations. Goldman Sachs initiated coverage with a 'Sell' rating for United Therapeutics and similarly rated Sagimet Biosciences. This action by one of Wall Street's most influential firms has led to immediate market reactions, signaling concerns about the future performance or valuations of these biotech stocks.
Topics: biotech stock ratings